Asymchem Laboratories (Tianjin) Co., Ltd. (HKG: 6821)

Market Cap	27.57B
Revenue (ttm)	6.17B
Net Income (ttm)	851.80M
Shares Out	n/a
EPS (ttm)	2.39
PE Ratio	32.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	Jun 13, 2024

Volume	1,600
Average Volume	149,371
Open	50.00
Previous Close	50.00
Day's Range	49.50 - 50.00
52-Week Range	37.60 - 79.15
Beta	0.16
RSI	49.92
Earnings Date	Mar 29, 2025

About Asymchem Laboratories (Tianjin)

Asymchem Laboratories (Tianjin) Co., Ltd. provides clinical stage CDMO, commercial stage CDMO, and emerging services in Mainland China and internationally. The company offers process development and optimization, analytical, and scale-up services for small molecule drug products throughout the pre-clinical and clinical stage; and ton-scale manufacturing services for registered starting materials, advanced intermediates, and active pharmaceutical ingredients. It also engages in pre-formulation and formulation development; provision of chemical m...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 9,788
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6821

Financial Performance

In 2023, Asymchem Laboratories (Tianjin)'s revenue was 7.83 billion, a decrease of -23.70% compared to the previous year's 10.26 billion. Earnings were 2.27 billion, a decrease of -31.28%.

Financial numbers in CNY